期刊文献+

基质金属蛋白酶-3基因启动子5A/6A多态性与高血压病的关系 被引量:1

Association between the matrix metalloproteinase 3 promoter 5A/6A polymorphism and essential hypertension
原文传递
导出
摘要 目的探讨基质金属蛋白酶-3(MMP-3)基因启动子-1171(5A/6A)多态性对兰州地区汉族人群高血压病发病的可能影响。方法采用限制性片段长度多态性分析技术,检测高血压病患者(高血压病组,104例)和正常者(对照组,102例)MMP-3基因启动子SNP-1171(5A/6A)基因型的分布。结果高血压病组与对照组MMP-3基因型分布差异无统计学意义,按性别分组比较两组男性、女性之间差异均无统计学意义(P<0.05),Logistic回归分析发现男性50岁以下病例组与对照组比较差异有统计学意义(P=0.013)。并且患高血压的危险性将增加5.97倍。不同血压分级之间基因型分布和等位基因频率比较无差异(分别为P=0.950,P=0.885)。结论MMP-3基因启动子-1171(5A/6A)多态性对高血压病发病的影响与性别年龄有关,与血压水平无关。 Objective to investigate the possible impact of the polymorphism in 5A/6A MMP-3 gene promoter on the risk of essential hypertension in Han Lanzhou area population. Methods 104 hypertensive patients( hypertensive group) and 102 normal persons control were recruited. Polymerase chainreaction followed by restrictionfragment length polymorphism (PCR-RFLP) was used to detect SNP-1171 (5A/6A) in MMP-3 gene promoter region. Results The distribution of MMP-3 genotype was not significantly different between hypertensive patients and controls. After dividing Study sample by gender, Distribution of MMP-3 genotype and allele frequencies also were not significantly different between hypertensive and normotensive neither males nor females ( P 〈 0.05 ). When Multiple logistic regression analysis was used, we found 5.97-fold increased risk for hypertension associated with genotype 6A/6A (P = 0.013 ) in young males ( 〈 50 years) according to recessive model. No significantly differences among different blood pressure level. Conclusion These results indicate that there was gender and age-specific differences in association of MMP-3 5A/6A polymorphism with hypertension in Lanzhou Han population. No marked association could be found between 5A/6A polymorphism in MMP-3 gene and different blood pressure level ( P =0. 950.P =0. 885 ) .
出处 《临床内科杂志》 CAS 2007年第11期776-778,共3页 Journal of Clinical Internal Medicine
关键词 基质金属蛋白酶-3 基因多态性 高血压病 Matrix metalloproteinase-3 Polymorphism Hypertension
  • 相关文献

参考文献10

  • 1Intengan HD,Schiffrin EL.Vascular Remodeling in Hypertension.Roles of Apoptosis,Inflammation,and Fibrosis.Hypertension,2001,38:581-587.
  • 2Tanja Rundek,Mitchell S,Elkind,et al.Carotid Intima-Media Thickness Is Associated With Allelic Variants of Stromelysin-1,Interleukin-6,and Hepatic Lipase Genes.Stroke,2002,33:1420-1423.
  • 3Giorgio Ghilardi,Maria Luisa Biondi,Marco DeMonti,et.al.Matrix Metalloproteinase-1 and Matrix Metalloproteinase-3 Gene Promoter Polymorphisms Are Associated With Carotid Artery Stenosis.Stroke,2002,33:2408-2412.
  • 4Kang Shan,Wang Ying,Zhang Jian-Hui,et al.The function of the SNP in the MMP1 and MMP3 promoter in susceptibility to endometriosis in China.Molecular Human Reproduction,2005,11:423 -427.
  • 5Djuric T,Zivkovic M,Stankovic A,et al.Endothelial NOS G894 T and MMP-3 5A/6A gene polymorphisms and hypertension in Serbian population.J ClinLabAnal,2005,19:241-246.
  • 6Alaina K,Natoli,Tanya L,et al.Sex Steroids Modulate Human Aortic Smooth Muscle Cell Matrix Protein Deposition and Matrix Metalloproteinase Expression Hypertension,2005,46:1129-1134.
  • 7Ahimastos AA,Formosa M,Dart AM,et al.Gender differences in large artery stiffness pre-and post puberty.J Clin Endocrinol Metab,2003,88:5375-5380.
  • 8康照梅,牟善初,张晓英,康秋风.MMP-2、MMP-3、TIMP-1及氯沙坦与氨氯地平在老年前期自发性高血压大鼠肾硬化中的作用及其机理探讨[J].中华老年多器官疾病杂志,2003,2(3):211-215. 被引量:5
  • 9Sasamura H,Kitamura Y,Nakamura M,et al.Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension.Clin Exp Hypertens,2006,28:511-520.
  • 10Tanya L,Medley,Bronwyn A.et al.Matrix etalloproteinase-3 Genotype Contributes to Age-Related Aortic Stiffening Through Modulation of Gene and Protein Expression Circ.Res,2003,92:1254-1261.

二级参考文献12

  • 1[1]Porush JG. Hypertension and chronic renal failure: the useof ACE inhibitors. Am J Kidney Dis, 1998, 31: 177-184.
  • 2[2]Chandler S, Miller KM, Clements JM, et al. Matrix met alloproteinases, tumor necrosis factor and multiple sclero sis: an overview. J Neuroimrmunol, 1997, 72:155-161.
  • 3[3]Ries C, Petrides PE. Cytokine regulation of matrix metal loproteinase activity and its regulatory dysfunction in dis ease. Biol Chem Hoppe Seyler, 1995, 376: 345-355.
  • 4[4]Suzuki D, Miyazaki M, Jinde K, et al. In situ hybridiza tion studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type Ⅳ collagen in diabetic nephropathy. Kidney Int, 1997, 52:111-119.
  • 5[5]Rawlings ND, Barrett AJ. Evolutionary families of metal- lopeptidases. Methods Enzymol, 1995,248:183-228.
  • 6[6]Steinmann-Niggli K, Ziswiler R, Kung M, et al. Inhibition of matrix metalloproteinases attenuates anti-Thy1. 1 nephri tis. J Am Soc Nephrol, 1998, 9:397-407.
  • 7[7]Baker AH, Zaltsman AB, George SJ, et al. Divergent ef fects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apop tosis. J Clin Invest, 1998, 101:1478-1487.
  • 8[8]Mai M, Geiger H, Hilgers KF, et al. Early interstitial changes in hypertension-induced renal injury. Hyperten sion, 1993, 22:754-765.
  • 9[9]Razzaque MS, Cheng M, Horita Y, et al. Immunohisto chemical analysis of type Ⅲ and Ⅳ collagens in tubuloint erstitial damage in human benign nephrosclerosis. J Int Med Res, 1995, 23:480-486.
  • 10[10]Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int, 1997, 51: 2-15.

共引文献4

同被引文献17

  • 1Ye S, Watts GF, Mandalia S, et al. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis[J]. Br Heart J, 1995, 73(3): 209-15.
  • 2Wu N, Lu X, Hua Y, et al. Haplotype analysis of the stromelysin-1 (MMP3) and gelatinase B (MMP9) genes in relation to coronary heart disease[J]. Ann Hum Genet, 2009, 73(Pt 4): 404-10.
  • 3Abilleira S, Bevan S, Markus HS. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis [J]. J Med Genet, 2006, 43(12): 897-901.
  • 4Seifi M, Fallah S, Firoozrai M. Influence of genetic polymorphism in matrix metalloproteinase-3 on extent of coronary atherosclerosis and risk of coronary artery stenosis[J]. Arch Med Res, 2009, 40(7): 600-4.
  • 5Beilby JP, Chapman CM, Palmer LJ, et al. Stromelysin-1 (MMP-3) gene 5A/6A promoter polymorphism is associated with blood pressure in a community population [J]. J Hypertens, 2005, 23(3): 537-42.
  • 6Djuric T, Zivkovic M, Stankovic A, et al. Endothelial NOS G894 T and MMP-3 5A/6A gene polymorphisms and hypertension in serbian population[J]. J Clin Lab Anal, 2005, 19(6): 241-6.
  • 7Lanfear DE, Marsh S, Cresci S, et al. Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans [J]. J Am Coil Cardiol, 2004, 44(1): 165-7.
  • 8Ozktik E, Aydin M, Babalik E, et al. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients [J]. Med Sci Monit, 2008, 14(10): CR536-42.
  • 9Fallah S, Seifi M, A. Risk of coronary artery stenosis in Iranian type 2 diabetics: is there a role for matrix metalloproteinase-3 gene (-1612 5A/6A) polymorphism [J]? J Physiol Biochem, 2010, 66(4): 359-64.
  • 10Liu PY, Li YH, Chart SH, et al. Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome [J]. Am J Cardiol, 2006, 98(8): 1012-7.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部